NTRA Stock Price Today (October 2026) — Natera, Inc. Analysis & Key Metrics 2026-10-07
Natera, Inc. (NTRA) is trading at $395.56, down 1.27% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $355.93 (10.0% downside).
- Volatility is moderate (36.62% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (37.70% YoY) alongside competitive pressures in the Diagnostics & Research space.
NTRA Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Natera, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $56.16B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
-10.0% downside from target
Key Investor Questions About NTRA
What investors need to know before buying
Based on current market data, NTRA presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 55.17)
- Fundamentals say: Looking solid (debt and growth supportive)
NTRA's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTRA investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $238.49M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, NTRA stock traded between $160.59 and $427.47 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 36.62% annualized volatility and β=1.16, the stock exhibits high sensitivity to market moves—making NTRA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar
Check out the companies making headlines yesterday:
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
Why Is Natera (NTRA) Stock Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceuticals and Medical Devices Agency granted regulatory approval for its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.
NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.
Why Natera (NTRA) Is Up 12.3% After Landmark Lung Cancer MRD Data At IASLC 2026
Natera and its collaborators recently presented four abstracts at the IASLC 2026 World Conference on Lung Cancer, including the largest molecular residual disease dataset to date in resected stage 1–3 non-small cell lung cancer, showing that Signatera status after surgery is strongly associated with recurrence-free survival and overall survival. An important insight from these data is that Signatera-positive patients had around five times the risk of recurrence or death during surveillance,...
Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions
Natera’s updated analyst models now point to a higher Fair Value price target of US$344.33, up from US$282.14, which is roughly a 22% change in the modeled outcome. Analysts are tying this shift to how Natera is executing in molecular residual disease testing with Signatera, along with contributions from prenatal and broader oncology testing and recent regulatory and reimbursement developments. As you read on, you will see how this evolving narrative may shape how you track Natera from...
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000
The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.
Natera Stock Has Excellent Technical ‘DNA’ as NTRA Sets a New All-Time High
Natera (NTRA) demonstrates strong technical momentum, with shares hitting a new all-time high. Shares are up more than 105% over the past year. Valuation concerns persist, as Morningstar sees NTRA as 33% overvalued and multiple analysts rate it a “Hold” despite bullish technicals. I recommend holding NTRA while it trades...
When To Sell Stocks: Why Investors May Want To Walk Away From These IBD 50 Stocks
With the stock market on shaky ground, investors should be adjusting their portfolio management and taking some profits. For about a half-dozen components of Investor's Business Daily's IBD 50 list, the decision on when to sell stocks is at hand. IBD's recommended market exposure is 40%-60%, so let's look at the gains that could be worth cashing in.
3 Reasons Investors Love Natera (NTRA)
What a time it’s been for Natera. In the past six months alone, the company’s stock price has increased by a massive 59.9%, reaching $328.13 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Explore More Analysis for NTRA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Natera, Inc.
Natera, Inc. (NTRA) is currently trading at $395.56. The RSI (14-day) is at 55.2, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $355.93 implies 10.0% downside from current levels. Volatility is moderate at 36.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Natera, Inc. (NTRA): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 26.95. Price-to-Sales is 18.20. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering NTRA, the consensus price target is $355.93. This represents a 10.0% downside from the current price of $395.56. The range spans from a low target of $280.00 to a high target of $460.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Natera, Inc. (NTRA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Natera, Inc. (NTRA) investors include: 1. Moderate volatility (36.6% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Natera, Inc.'s (NTRA) current debt and financial health profile: Total debt stands at $238.49M. The debt-to-equity ratio is 0.13x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.00, indicating strong short-term liquidity. The quick ratio is 2.74. The company holds $1.09B in cash and equivalents. Free cash flow is positive at $104.03M, providing a cushion for debt servicing and shareholder returns.